(Acetaminophen + nefopam hydrochloride) is under clinical development by Aptys Pharmaceuticals and currently in Phase III for Somatic Pain. According to GlobalData, Phase III drugs for Somatic Pain have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Acetaminophen + nefopam hydrochloride)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Acetaminophen + nefopam hydrochloride) overview
Metapain, a fixed dose oral combination of nefopam and paracetamol is under development for the treatment of moderate to severe pain.
Aptys Pharmaceuticals overview
APTYS Pharmaceuticals (APTYS) operates as a contract research and development organization that manufactures, develops, and markets pharmaceutical drugs and formulations. The organization’s products include adhapt that is a protein-based bio-adhesive tablet and Bio-gel that is a semi-solid dosage form used for topical and transdermal applications. It offers its products in the areas of ophthalmology, dermatology, pneumology, gastroenterology, infectiology, oncology, and pediatrics, among others. APTYS offers services such as analytical development, formulations development, consulting and support services, among others. The organization markets its products through its distributors located in France. APTYS is headquartered in Saint Beauzire, Pays-de-la-Loire, France.
For a complete picture of (Acetaminophen + nefopam hydrochloride)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
